Guizhou Xinbang Pharmaceutical Co Ltd (002390) — Tangible Net Worth Ratio
Guizhou Xinbang Pharmaceutical Co Ltd (002390) has a Tangible Net Worth Ratio of 97.4% as of September 2025. This metric is calculated by deducting intangible assets (CN¥180.04 Million) from net assets (CN¥6.97 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore net asset growth rate of Guizhou Xinbang Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Guizhou Xinbang Pharmaceutical Co Ltd Tangible Net Worth Ratio (2006–2024)
This chart shows how Guizhou Xinbang Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 19 annual periods from 2006 to 2024. As of September 2025, the ratio stands at 97.4%, reflecting net assets of CN¥6.97 Billion with intangible assets of CN¥180.04 Million CNY. Check 002390 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Annual Tangible Net Worth Ratio for Guizhou Xinbang Pharmaceutical Co Ltd (2006–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Guizhou Xinbang Pharmaceutical Co Ltd from 2006 to 2024, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see 002390 company net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 97.3% | CN¥7.02 Billion | CN¥189.54 Million | CN¥9.03 Billion | ▼ -0.2 pp |
| 2023 | 97.5% | CN¥7.14 Billion | CN¥180.18 Million | CN¥9.24 Billion | ▲ +0.4 pp |
| 2022 | 97.1% | CN¥7.07 Billion | CN¥204.37 Million | CN¥9.79 Billion | ▲ +0.3 pp |
| 2021 | 96.8% | CN¥6.83 Billion | CN¥217.65 Million | CN¥9.63 Billion | ▲ +1.1 pp |
| 2020 | 95.8% | CN¥5.17 Billion | CN¥219.56 Million | CN¥9.66 Billion | ▲ +1.8 pp |
| 2019 | 93.9% | CN¥5.05 Billion | CN¥307.78 Million | CN¥10.42 Billion | ▲ +0.3 pp |
| 2018 | 93.7% | CN¥5.17 Billion | CN¥328.04 Million | CN¥10.85 Billion | ▼ -1.4 pp |
| 2017 | 95.0% | CN¥6.76 Billion | CN¥336.59 Million | CN¥11.95 Billion | ▲ +0.4 pp |
| 2016 | 94.6% | CN¥6.49 Billion | CN¥348.54 Million | CN¥10.80 Billion | ▲ +0.8 pp |
| 2015 | 93.8% | CN¥2.67 Billion | CN¥165.97 Million | CN¥6.50 Billion | ▼ -0.3 pp |
| 2014 | 94.1% | CN¥2.46 Billion | CN¥144.37 Million | CN¥5.22 Billion | ▼ -2.9 pp |
| 2013 | 97.0% | CN¥1.04 Billion | CN¥30.63 Million | CN¥1.49 Billion | ▼ -0.6 pp |
| 2012 | 97.6% | CN¥1.02 Billion | CN¥24.33 Million | CN¥1.33 Billion | ▼ -1.1 pp |
| 2011 | 98.7% | CN¥979.53 Million | CN¥12.47 Million | CN¥1.24 Billion | ▼ -0.1 pp |
| 2010 | 98.8% | CN¥959.70 Million | CN¥11.11 Million | CN¥1.13 Billion | ▲ +3.5 pp |
| 2009 | 95.4% | CN¥252.83 Million | CN¥11.74 Million | CN¥470.35 Million | ▼ -0.1 pp |
| 2008 | 95.5% | CN¥207.69 Million | CN¥9.38 Million | CN¥442.73 Million | ▲ +1.2 pp |
| 2007 | 94.3% | CN¥174.08 Million | CN¥9.89 Million | CN¥391.07 Million | ▼ -3.8 pp |
| 2006 | 98.1% | CN¥144.17 Million | CN¥2.71 Million | CN¥379.34 Million | — |